Levemir Flextouch

Insulin detemir, the active ingredient in Levemir Flextouch, is a long‑acting insulin analog presented as a solution for injection, prefilled pen for subcutaneous use. It provides basal insulin replacement to help manage blood glucose levels in adults with type 1 and type 2 diabetes mellitus. It is indicated for basal insulin therapy and is administered once or twice daily depending on individual glycemic targets.

GNH USA supplies Levemir Flextouch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable cold‑chain logistics.

Levemir Flextouch, a long‑acting insulin analog, is used to provide basal insulin coverage in diabetes management.

- Type 1 diabetes mellitus: maintains fasting glucose levels and reduces the need for frequent short‑acting insulin doses. - Type 2 diabetes mellitus: supports basal insulin requirements when oral agents are insufficient. - Diabetes mellitus (general): offers steady insulin action to help achieve target HbA1c levels.

Levemir Flextouch may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in fat tissue at injection sites. - Edema: mild fluid retention in extremities.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases. - Insulin antibody formation: may alter insulin effectiveness. - Diabetic ketoacidosis (rare): metabolic decompensation if insulin is insufficient.

When prescribing or handling Levemir Flextouch, several precautions should be observed to ensure safety and efficacy.

- Dose titration: adjust based on regular blood glucose monitoring and clinical response. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose. - Renal or hepatic impairment: monitor closely as insulin clearance may be altered. - Concomitant medications: review for agents that may potentiate hypoglycemia. - Pregnancy and lactation: use only if benefits outweigh potential risks, after medical evaluation. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the pen.

Levemir Flextouch can interact with other medicines, affecting glucose control or insulin action.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): combined use can cause severe hypoglycemia. - Excessive alcohol intake: may potentiate hypoglycemic episodes.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can mask hypoglycemia symptoms, requiring closer glucose monitoring. - Thiazide diuretics: may increase blood glucose, potentially requiring dose adjustment. - Systemic corticosteroids: can raise glucose levels, often necessitating higher insulin doses.